Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Long-Term Investments (2023 - 2026)

Maxcyte has reported Long-Term Investments over the past 3 years, most recently at $52.6 million for Q4 2025.

  • Quarterly Long-Term Investments rose 46.92% to $52.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.6 million through Dec 2025, up 46.92% year-over-year, with the annual reading at $52.6 million for FY2025, 46.92% up from the prior year.
  • Long-Term Investments was $52.6 million for Q4 2025 at Maxcyte, up from $52.3 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $52.6 million in Q4 2025 and troughed at $18.4 million in Q3 2023.
  • The 3-year median for Long-Term Investments is $42.6 million (2024), against an average of $40.7 million.
  • Year-over-year, Long-Term Investments soared 132.23% in 2024 and then dropped 19.12% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $42.9 million in 2023, then dropped by 16.67% to $35.8 million in 2024, then soared by 46.92% to $52.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Long-Term Investments are $52.6 million (Q4 2025), $52.3 million (Q3 2025), and $38.6 million (Q2 2025).